RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Oncternal Therapeutics EBIT 2024

Oncternal Therapeutics EBIT

-39.7 M USD

Oncternal Therapeutics Dividend yield

Ticker

ONCT

ISIN

US68236P1075

WKN

A2PL3P

In 2024, Oncternal Therapeutics's EBIT was -39.7 M USD, a -4.83% increase from the -41.71 M USD EBIT recorded in the previous year.

The Oncternal Therapeutics EBIT history

YEAREBIT (undefined USD)
2030e159.09
2029e82.19
2028e-65.54
2027e-65.54
2026e-58.14
2025e-50.31
2024e-39.7
2023-41.71
2022-44.95
2021-31.37
2020-17.54
2019-33.11
2018-39.06
2017-30.66
2016-25.93
2015-21.84
2014-30.35
2013-43.6
2012-49.73
2011-35.9
201015.1
2009-46.68
2008-54.52
2007-45.67
2006-38.52
2005-38.56
2004-23.29

Oncternal Therapeutics Aktienanalyse

What does Oncternal Therapeutics do?

Oncternal Therapeutics Inc is an American biotechnology company specializing in the development of cancer drugs. The company was founded in 2013 and is headquartered in San Diego, California. Oncternal Therapeutics' business model is based on identifying promising cancer drugs and advancing them through the approval process of regulatory authorities. The company utilizes both public and private funds to finance its research projects. As part of this, Oncternal Therapeutics participates in clinical trials and actively collaborates with experts in the clinical field. Over the years, the company has established several divisions to make its work more effective and efficient. One of these divisions focuses on developing molecules that activate the body's immune system against cancer cells. A prime example of this is the drug Cirmtuzumab. This antibody blocks signals that promote the growth of cancer cells while simultaneously activating the immune system to target tumor cells. Cirmtuzumab has shown positive results in the treatment of chronic lymphocytic leukemia, a form of blood cancer. Another division of Oncternal Therapeutics focuses on developing drugs that target cancer stem cells. These cells are responsible for the growth and spread of cancer cells in the body. Medications like the ROR1-targeting CAR-T preparation directly target these types of cancer cells and are intended to make cancer drugs more effective and targeted. Oncternal Therapeutics stands out from other cancer researchers in its ability to treat multiple myelomas, a cancer of the bone marrow cells, more effectively. The company has developed specific drugs that can influence the expression of specific genes in myeloma cells, thereby halting tumor growth. Key myeloma products from Oncternal Therapeutics include the TK216 and OT-82 preparations. In summary, Oncternal Therapeutics Inc is an innovative biotechnology company specializing in the development of cancer drugs. The company has a wide range of divisions, from developing drugs that activate the immune system against cancer cells to targeting cancer stem cells. The company's products show promising results in the treatment of various types of cancer and have the potential to bring about positive change for thousands of cancer patients worldwide. Oncternal Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Oncternal Therapeutics's EBIT

Oncternal Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oncternal Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oncternal Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oncternal Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oncternal Therapeutics Stock

How much did Oncternal Therapeutics achieve in EBIT for the current year?

In the current year, Oncternal Therapeutics has achieved an EBIT of -39.7 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Oncternal Therapeutics.

How has the EBIT of Oncternal Therapeutics developed in recent years?

The EBIT of Oncternal Therapeutics has increased by -4.832% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Oncternal Therapeutics?

The EBIT of Oncternal Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Oncternal Therapeutics pay?

Over the past 12 months, Oncternal Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncternal Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncternal Therapeutics?

The current dividend yield of Oncternal Therapeutics is .

When does Oncternal Therapeutics pay dividends?

Oncternal Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncternal Therapeutics?

Oncternal Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Oncternal Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncternal Therapeutics located?

Oncternal Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncternal Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncternal Therapeutics from 5/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Oncternal Therapeutics pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Oncternal Therapeutics in the year 2023?

In the year 2023, Oncternal Therapeutics distributed 0 USD as dividends.

In which currency does Oncternal Therapeutics pay out the dividend?

The dividends of Oncternal Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncternal Therapeutics

Our stock analysis for Oncternal Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncternal Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.